Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer
In Partnership With:
Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.
Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer (mCRPC) and the potential for combinations with this agent.
In this comparative analysis, African Americans with mCRPC receiving sipuleucel-T had a higher median overall survival when compared with Caucasian patients.
Regarding combinations with this agent, there are only hypothesized studies. There is still more to learn with sipuleucel-T, Sartor says.
